NVCR NovoCure Limited

-0.10  -0%
Previous Close 21.60
Open 21.60
Price To book 16.29
Market Cap 1913555363
Shares 89,002,575
Volume 575,772
Short Ratio 8.35
Av. Daily Volume 875,538

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 commencement of enrollment announced June 8, 2017.
Optune and bevacizumab
Refractory recurrent glioblastoma (GBM)
Phase 3 commencement of enrollment announced February 15, 2017. Data due 2021.
Tumor Treating Fields (TTFields) LUNAR
Non-small cell lung cancer (NSCLC)
Phase 2 data presented December 12, 2016. Further promising PFS data released March 31, 2017. Phase 3 trial to be initiated in 2018.
Tumor Treating Fields (TTFields) - INNOVATE
Ovarian cancer
Phase 2 data presented December 12, 2016. Phase 3 trial to be initiated 2H 2017.
Tumor Treating Fields (TTFields) - PANOVA
Pancreatic cancer
Phase 3 enrollment commenced October 2016. Data due 2020.
Tumor Treating Fields (TTFields) METIS
Brain Metastases Originating from Non-Small Cell Lung Cancer
Phase 2 enrollment completion announced March 31, 2017. Data likely 2Q 2018.
Tumor Treating Fields (TTFields) STELLAR

Latest News

  1. Novocure Announces Data Presentations at the American Society for Radiation Oncology’s 2017 Annual Meeting
  2. 3 Innovation-Forward Healthcare Stocks to Buy Now
  3. Dolby Laboratories is a stock to watch after Apple’s new iPhone launch
  4. Novocure Announces Data Presentations at the ESMO 2017 Congress
  5. German Federal Joint Committee Announces Decision to Support a Clinical Trial to Study Optune® for the Treatment of Newly Diagnosed Glioblastoma
  6. If You Love Intuitive Surgical, You Should Check Out This Small-Cap Growth Stock
  7. Novocure to Present at Two Upcoming Investor Conferences in September
  8. Edited Transcript of NVCR earnings conference call or presentation 27-Jul-17 12:00pm GMT
  9. 3 Stocks That Could Soar More Than Priceline
  10. 3 Game-Changing Small-Cap Healthcare Stocks
  11. ETFs with exposure to Novocure Ltd. : August 11, 2017
  12. Novocure™ Announces National Reimbursement for Optune® in Austria
  13. 3 Exciting Biotechs Under $30: Novocure Is Revolutionizing Brain Cancer Treatment
  14. Novocure to Present at the 2017 Wedbush PacGrow Healthcare Conference
  15. 3 Hot Healthcare Stocks Under $30
  16. Novocure Ltd. :NVCR-US: Earnings Analysis: Q2, 2017 By the Numbers : July 28, 2017
  17. NovoCure reports 2Q loss
  18. Investor Network: Novocure Ltd. to Host Earnings Call
  19. Novocure Reports Second Quarter 2017 Financial Results and Provides Company Update
  20. Novocure™ Announces a Phase 1b Clinical Trial to Evaluate the Safety of Marizomib and Temozolomide in Combination with Optune® as Adjuvant Therapy in Patients with Glioblastoma